OXFORD, England–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia’s People (human resources) and Places functions and build on the Company’s talent, training and employee experience strategies. Caroline reports to CEO and Founder, Andrew Hopkins, DPhil. “Exscientia was … [Read more…]
LAUSANNE, Switzerland & TEL AVIV, Israel–(BUSINESS WIRE)–#biomarker—Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the … [Read more…]
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptive Cataract Treatment System (“ALLY” or the “ALLY System”) in the European Union. “Following the FDA clearance of ALLY … [Read more…]
– New state-of-the art manufacturing facility is designed to enable the reliable production of Orca Bio’s investigational cell therapies from late-stage clinical development through potential commercialization – – The 100,000-square-foot facility is located in Metro Air Park, Sacramento – MENLO PARK, Calif.–(BUSINESS WIRE)–Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment … [Read more…]
– Phosphorylation-inducing chimeric small molecules (PHICS) are a new class of bifunctional medicines that direct and repair aberrant and dysfunctional proteins – PHICS enable precise phosphorylation, an important post-translational modification that controls protein function, including activation, stabilization, trafficking, inactivation, and degradation – Led by a strong foundational management team of respected industry veterans with deep … [Read more…]
IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15™, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system. The University of Alberta implanted four … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering. The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape” report has been added to ResearchAndMarkets.com’s offering. This reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics. Synopsis In 2022, there will be more than 14,000 incident cases of WM across 16 pharmaceutical … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Dental Implants and Prosthesis – Market Insights, Competitive Landscape and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering. The global dental implants and prosthesis market was valued at USD 10.42 billion in 2021, growing at a CAGR of 7.79 % during the forecast period from 2022 to 2027 to reach USD 16.35 … [Read more…]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the CE marking of its PCR kit which measures circulating microRNA-132 (miR-132) levels in the blood of patients receiving the company’s lead candidate CDR132L, an oligonucleotide-based miR-132 inhibitor. The company is currently conducting its Phase … [Read more…]
